Clinical Trials Logo

Septic Shock clinical trials

View clinical trials related to Septic Shock.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06370078 Not yet recruiting - Septic Shock Clinical Trials

Effect of Early Administration of Albumin 20% Versus Crystalloid

Start date: May 1, 2024
Phase: N/A
Study type: Interventional

Sepsis and septic shock are global health problems, leading to a high mortality rate. They are often associated with extremely low blood pressure and multiple organ dysfunctions, which are the main causes of death in critically ill patients. Fluid resuscitation is one of the most critical treatments for patients with sepsis and septic shock. An early administration of an appropriate fluid to patients is considered the most effective way to increase blood pressure, improve tissue perfusion, and save their lives. Crystalloid fluids are a subset of intravenous solutions composed of mineral salts and other small, water-soluble molecules, including normal, isotonic or hypertonic saline, and various buffered solutions.

NCT ID: NCT06366854 Not yet recruiting - Septic Shock Clinical Trials

UK ANDROMEDA-Shock-2 RCT

Start date: May 1, 2024
Phase: N/A
Study type: Interventional

The purpose of the trial is to test if a strategy of resuscitation guided by capillary refill time and individualised clinical hemodynamic phenotyping can improve important clinical outcomes within 28 days in septic shock patients compared to usual care.

NCT ID: NCT06330610 Not yet recruiting - Septic Shock Clinical Trials

Evaluation of the Efficiency of Intermittent Enteral Nutrition on Multi-organ Failure From Patients With Mechanical Ventilation in Intensive Care Unit

ENNUT-CI
Start date: May 1, 2024
Phase: N/A
Study type: Interventional

This study aims to evaluate the efficiency of intermittent enteral nutrition versus continuous enteral nutrition to prevent from organ failures for patients at the acute phase of sepsis shock with mechanical ventilation in ICU.

NCT ID: NCT06302998 Not yet recruiting - Sepsis Clinical Trials

Dexmedetomidine and Vasopressin in Septic Shock

DecatSepsis-2
Start date: June 2024
Phase: Phase 2
Study type: Interventional

Rudiger and Singer suggested strategies for refining adrenergic stress (decatecholaminization). They proposed the use of dexmedetomidine and vasopressin to reduce the catecholamine load during sepsis. The investigators will use vasopressin as the primary vasopressor and a heart rate-calibrated dexmedetomidine infusion in septic shock patients. The investigators of the current study will use DEXPRESSIN in septic shock patients to investigate the effects of decatecholaminization on in-hospital mortality.

NCT ID: NCT06258291 Not yet recruiting - Septic Shock Clinical Trials

First in Human Trial to Assess the Safety & Efficacy of HemoSystem REBOOT in Patients With Sepsis-induced Immunosuppression

(RESTORE)
Start date: September 15, 2024
Phase: N/A
Study type: Interventional

The aim of this randomized controlled trial is to restore immune function by selectively removing three mediators largely contributing to sepsis-induced immunosuppression from extracorporeal circulation.

NCT ID: NCT06234592 Not yet recruiting - Acute Kidney Injury Clinical Trials

The Effect of Vasopressor Therapy on Renal Perfusion in Septic Shock

REPERFUSE
Start date: January 2024
Phase: N/A
Study type: Interventional

Acute kidney injury (AKI) is a common complication of septic shock and together these conditions carry a high mortality risk. In septic patients who develop severe AKI renal cortical perfusion is deficient despite normal macrovascular organ blood flow. This intra-renal perfusion abnormality may be amenable to pharmacological manipulation, which may offer mechanistic insight into the pathophysiology of septic AKI. The aim of the current study is to investigate the effects of vasopressin and angiotensin II on renal microcirculatory perfusion in a cohort of patients with septic shock.

NCT ID: NCT06227702 Not yet recruiting - Septic Shock Clinical Trials

Vexus-guided Fluid Management in Patients With Septic Shock After the Resuscitation Phase

VEXUS
Start date: February 1, 2024
Phase: N/A
Study type: Interventional

It is well recognized the association between fluid volume administered and positive fluid balance with adverse outcomes . Active fluid removal is widely practiced in an attempt to mitigate this potential damage. However, it is not clear which is the best approach for the post-resuscitation phase in critically ill patients. In this context, Point-of-Care ultrasound (POCUS) through Venous Excess Ultrasound (VExUS) would allow the assessment of the degree of venous congestion, through the visualization of vascular anatomy and blood velocity using Doppler, being potentially useful to guide fluid removal. The investigators will evaluate whether fluid management after the initial phase of VExUS-guided resuscitation is able to improve outcomes compared to usual therapy in patients with septic shock. This is a single center, prospective, open and randomized clinical study in which patients admitted to intensive care will be included after the first 24 hours of resuscitation. A total of 200 patients will be randomized either to volume management guided by VExUS or to the standard therapy arm as per usual practice.

NCT ID: NCT06184659 Not yet recruiting - Sepsis Clinical Trials

Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis

EMPRESS
Start date: August 1, 2024
Phase: Phase 4
Study type: Interventional

The EMPRESS trial aims to test the two most commonly used antibiotics (meropenem and piperacillin/tazobactam) among intensive care patients with sepsis (blood poisoning), as the safety of these two drugs is unclear in this group of patients.

NCT ID: NCT06156072 Not yet recruiting - Sepsis Clinical Trials

Ultrasound-guided Blood Sampling Drawing for Microbiological Analysis in the Critically Ill

ECOVEN
Start date: April 2024
Phase:
Study type: Observational

This study will test the feasibility of ultrasound-guided sterile blood sampling for critically ill patients with suspected sepsis requiring blood culture. The aim of the study is to evaluate the feasibility and safety of the use of ultrasound for blood cultures in a population of patients which can present difficult venous access and requiring more than one venipuncture attempt in general clinical practice

NCT ID: NCT06156059 Not yet recruiting - Septic Shock Clinical Trials

Oral Bedtime Melatonin in Critically Ill Patients

Mel-ICU
Start date: February 1, 2025
Phase: Phase 4
Study type: Interventional

Oxidative stress is one of the main mechanisms causing harm in severe infection with septic shock, ischemia-reperfusion injury in resuscitated cardiac arrest and ischemic and hemorrhagic stroke. Melatonin is a potent scavenger of the mediators of oxidative stress, oxygen and nitrogen-reactive species, which directly injure cell structures like walls and DNA and thus cause organ dysfunction. In a previous study we have observed that high-dose oral bedtime melatonin (OBM) is associated with improved organ function in severe Covid-19 patients